Unnamed: 0,title,date,stock,sentiment
946043.0,"Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.",2020-06-08 11:41:00-04:00,OCUL,positive
946044.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,OCUL,neutral
946045.0,"Ocular Therapeutix shares are trading lower after the company priced its 8.18 million share offering of its common stock at $5.50 per share. UPDATE: Shares have since reversed, now higher.",2020-05-20 09:02:00-04:00,OCUL,positive
946046.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,OCUL,neutral
946047.0,Ocular Therapeutix Says Public Offering Of 8.18M Common Shares Priced At $5.50/Share,2020-05-20 07:33:00-04:00,OCUL,positive
946048.0,Ocular Therapeutix Announces Proposed Public Offering of Common Stock; Size Not Disclosed,2020-05-19 16:44:00-04:00,OCUL,neutral
946049.0,70 Biggest Movers From Friday,2020-05-18 04:47:00-04:00,OCUL,neutral
946050.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,OCUL,negative
946051.0,Ocular Therapeutix Announces First Patient Dosed In Phase 1 Clinical Trial Of OTX-CSI For The Treatment Of Dry Eye Disease,2020-05-12 07:16:00-04:00,OCUL,neutral
946052.0,Ocular Therapeutix: Q1 Earnings Insights,2020-05-08 08:43:00-04:00,OCUL,neutral
946053.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,OCUL,neutral
946054.0,"Ocular Therapeutix Q1 GAAP EPS $(0.410) May Not Compare $(0.370) Estimate, Sales $2.600M Miss $2.840M Estimate",2020-05-08 07:12:00-04:00,OCUL,negative
946055.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,OCUL,neutral
946056.0,Ocular Therapeutix shares are trading higher after HC Wainwright maintained its Buy rating on the stock and raised its price target from $8 to $10 per share.,2020-04-29 08:42:00-04:00,OCUL,positive
946057.0,"HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $10",2020-04-29 07:25:00-04:00,OCUL,neutral
946058.0,34 Stocks Moving in Tuesday's Pre-Market Session,2020-04-28 07:16:00-04:00,OCUL,neutral
946059.0,UPDATE: Ocular Therapeutix Says Intends To Submit Supplemental New Drug Application To Expand DEXTENZA's Label To Include Treatment Of Ocular Itching Associated With Allergic Conjunctivitis In 2020,2020-04-28 07:09:00-04:00,OCUL,neutral
946060.0,Ocular Therapeutix Reports Data From Phase 3 Trial Showed Statistically Significance Effect Achieved At All Pre-Specified Primary Endpoints,2020-04-28 07:09:00-04:00,OCUL,positive
946061.0,"Jefferies Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces $8 Price Target",2020-03-17 10:22:00-04:00,OCUL,neutral
946062.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,OCUL,negative
946063.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,OCUL,negative
946064.0,"Earnings Scheduled For March 12, 2020",2020-03-12 04:51:00-04:00,OCUL,neutral
946065.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,OCUL,negative
946066.0,"The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study",2020-03-06 08:49:00-05:00,OCUL,negative
946067.0,Stocks That Hit 52-Week Highs On Thursday,2020-03-05 10:18:00-05:00,OCUL,neutral
946068.0,"Piper Sandler Reiterates Overweight on Ocular Therapeutix, Raises Price Target to $11",2020-03-05 08:35:00-05:00,OCUL,negative
946069.0,"The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19",2020-03-05 08:05:00-05:00,OCUL,negative
946070.0,92 Biggest Movers From Yesterday,2020-03-05 04:41:00-05:00,OCUL,neutral
946071.0,Mid-Afternoon Market Update: Dow Jumps Over 800 Points; Cardlytics Shares Slide,2020-03-04 14:30:00-05:00,OCUL,positive
946072.0,60 Stocks Moving In Wednesday's Mid-Day Session,2020-03-04 12:11:00-05:00,OCUL,neutral
946073.0,Mid-Day Market Update: Owens & Minor Falls On Weak Sales; Cellect Biotechnology Shares Climb,2020-03-04 12:02:00-05:00,OCUL,negative
946074.0,Stocks That Hit 52-Week Highs On Wednesday,2020-03-04 10:24:00-05:00,OCUL,neutral
946075.0,Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:16:00-05:00,OCUL,positive
946076.0,85 Biggest Movers From Yesterday,2020-03-04 05:04:00-05:00,OCUL,neutral
946077.0,"Raymond James Upgrades Ocular Therapeutix to Strong Buy, Raises Price Target to $15",2020-03-03 14:24:00-05:00,OCUL,positive
946078.0,Ocular Therapeutix Reports Prelim. Q4 Sales $2.3M,2020-03-03 07:31:00-05:00,OCUL,neutral
946079.0,Stocks That Hit 52-Week Highs On Friday,2020-02-21 10:26:00-05:00,OCUL,neutral
946080.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,OCUL,negative
946081.0,"H.C. Wainwright Reiterates Buy on Ocular Therapeutix, Raises Price Target to $8",2020-02-10 07:19:00-05:00,OCUL,neutral
946082.0,Ocular Therapeutix Highlights Presentation Of Data Showing Clinically-Meaningful Reduction In Intraocular Pressure In Patients With Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference,2020-02-07 08:04:00-05:00,OCUL,negative
946083.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,OCUL,neutral
946084.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-01-21 12:14:00-05:00,OCUL,neutral
946085.0,53 Biggest Movers From Friday,2020-01-06 05:30:00-05:00,OCUL,neutral
946086.0,30 Stocks Moving In Friday's Mid-Day Session,2020-01-03 12:29:00-05:00,OCUL,neutral
946087.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,OCUL,neutral
946088.0,52 Biggest Movers From Friday,2019-12-02 04:44:00-05:00,OCUL,neutral
946089.0,35 Stocks Moving In Friday's Mid-Day Session,2019-11-29 11:40:00-05:00,OCUL,neutral
946090.0,52 Biggest Movers From Wednesday,2019-11-29 05:26:00-05:00,OCUL,neutral
946091.0,10 Biggest Price Target Changes For Friday,2019-11-15 08:37:00-05:00,OCUL,neutral
946092.0,"H.C. Wainwright Maintains Buy on Ocular Therapeutix, Lowers Price Target to $6",2019-11-15 07:31:00-05:00,OCUL,negative
946093.0,"JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $7",2019-11-13 07:40:00-05:00,OCUL,positive
946094.0,74 Biggest Movers From Yesterday,2019-11-13 04:42:00-05:00,OCUL,neutral
946095.0,"Ocular Therapeutix Q3 EPS $(0.45) Beats $(0.47) Estimate, Sales $829K Beat $580K Estimate",2019-11-12 08:00:00-05:00,OCUL,neutral
946096.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,OCUL,neutral
946097.0,58 Biggest Movers From Yesterday,2019-11-12 04:25:00-05:00,OCUL,neutral
946098.0,38 Stocks Moving In Monday's Mid-Day Session,2019-11-11 12:10:00-05:00,OCUL,neutral
946099.0,Ocular Therapeutix Inc To Allocate Capital And Resources To Maximize Commercial Opportunity Of Dextenza,2019-11-08 16:03:00-05:00,OCUL,positive
946100.0,Ocular Therapeutix Announces Strategic Update And Operational Restructuring; Plan Is Expected To Result In $11M In Annualized Savings,2019-11-08 16:02:00-05:00,OCUL,neutral
946101.0,"Ocular Therapeutix Announces Permanent J-Code For DEXTENZA Effective October 1, 2019",2019-10-01 16:25:00-04:00,OCUL,positive
946102.0,50 Biggest Movers From Yesterday,2019-09-27 04:31:00-04:00,OCUL,neutral
946103.0,Ocular Therapeutix Announces First Patient Dosed In Phase 3 Clinical Trial Of Dextenza For The Treatment Of Allergic Conjunctivitis,2019-09-24 08:03:00-04:00,OCUL,negative
946104.0,50 Biggest Movers From Yesterday,2019-08-27 05:20:00-04:00,OCUL,neutral
946105.0,Ocular Therapeutix Option Alert: Mar 20 $5 Calls Sweep (2) near the Ask: 500 @ $1.101 vs 235 OI; Ref=$4.28,2019-08-12 11:30:00-04:00,OCUL,positive
946106.0,110 Biggest Movers From Yesterday,2019-08-09 05:15:00-04:00,OCUL,neutral
946107.0,90 Stocks Moving In Thursday's Mid-Day Session,2019-08-08 12:50:00-04:00,OCUL,neutral
946108.0,Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results.,2019-08-08 09:52:00-04:00,OCUL,neutral
946109.0,25 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-08 08:35:00-04:00,OCUL,neutral
946110.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,OCUL,neutral
946111.0,"Ocular Therapeutix Q2 EPS $(0.57) Misses $(0.48) Estimate, Sales $650 Miss $740K Estimate",2019-08-07 16:02:00-04:00,OCUL,negative
946112.0,40 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-02 04:10:00-04:00,OCUL,neutral
946113.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-31 09:41:00-04:00,OCUL,neutral
946114.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,OCUL,neutral
946115.0,62 Biggest Movers From Friday,2019-07-29 05:47:00-04:00,OCUL,neutral
946116.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-26 10:09:00-04:00,OCUL,neutral
946117.0,"Ocular Therapeutix Reports Early Assignment Of Permanent, Specific J-Code (J1096) For DEXTENZA 0.4mg",2019-07-26 08:03:00-04:00,OCUL,neutral
946118.0,33 Biggest Movers From Friday,2019-07-08 05:44:00-04:00,OCUL,neutral
946119.0,24 Stocks Moving In Friday's Mid-Day Session,2019-07-05 12:41:00-04:00,OCUL,neutral
946120.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-07-02 08:07:00-04:00,OCUL,neutral
946121.0,Ocular Therapeutix Announces the Commercial Launch of DEXTENZA in the United States,2019-07-01 08:05:00-04:00,OCUL,positive
946122.0,68 Biggest Movers From Friday,2019-06-24 04:25:00-04:00,OCUL,neutral
946123.0,"Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More",2019-06-23 15:53:00-04:00,OCUL,neutral
946124.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-21 12:13:00-04:00,OCUL,neutral
946125.0,FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule,2019-06-21 11:19:00-04:00,OCUL,negative
946126.0,Ocular Therapeutix shares are trading higher after the company received FDA approval of its sNDA for DEXTENZA  for treatment of ocular inflammation following ophthalmic surgery.,2019-06-21 08:04:00-04:00,OCUL,positive
946127.0,Ocular Therapeutix Announces FDA Approval Of Supplemental New Drug Application For DEXTENZA For Treatment Of Ocular Inflammation Following Ophthalmic Surgery,2019-06-21 08:02:00-04:00,OCUL,positive
946128.0,48 Biggest Movers From Yesterday,2019-06-19 04:50:00-04:00,OCUL,neutral
946129.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-06-18 12:39:00-04:00,OCUL,neutral
946130.0,54 Biggest Movers From Yesterday,2019-06-14 05:02:00-04:00,OCUL,neutral
946131.0,66 Biggest Movers From Yesterday,2019-06-12 04:44:00-04:00,OCUL,neutral
946132.0,Social Media Posts Draw Attention To Recent Ocular Therapeutix Buys Ahead Of July 1st 'Soft Launch',2019-06-11 15:20:00-04:00,OCUL,neutral
946133.0,Ocular Therapeutics shares are trading higher potentially on trader optimism after a recent cluster of insider buying from management.,2019-06-11 15:01:00-04:00,OCUL,positive
946134.0,48 Stocks Moving In Tuesday's Mid-Day Session,2019-06-11 12:36:00-04:00,OCUL,neutral
946135.0,60 Biggest Movers From Friday,2019-06-10 06:41:00-04:00,OCUL,neutral
946136.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-07 12:50:00-04:00,OCUL,neutral
946137.0,64 Biggest Movers From Friday,2019-06-03 06:12:00-04:00,OCUL,neutral
946138.0,Ocular Therapeutix Announces Receipt Of New Reimbursement Code (C-Code) And Pass-Through Payment Status For DEXTENZA,2019-05-29 08:10:00-04:00,OCUL,neutral
946139.0,"The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study",2019-05-22 07:34:00-04:00,OCUL,neutral
946140.0,50 Biggest Movers From Yesterday,2019-05-22 05:12:00-04:00,OCUL,neutral
946141.0,Mid-Afternoon Market Update: Dycom Industries Rises On Upbeat Q1 Results; BioCryst Pharmaceuticals Shares Plummet,2019-05-21 14:36:00-04:00,OCUL,positive
946142.0,"Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline",2019-05-21 13:00:00-04:00,OCUL,neutral
946143.0,36 Stocks Moving In Tuesday's Mid-Day Session,2019-05-21 12:31:00-04:00,OCUL,neutral
946144.0,Mid-Day Market Update: CIRCOR Jumps Following $45/Share Bid From Crane; Ocular Therapeutix Shares Slide,2019-05-21 12:04:00-04:00,OCUL,positive
946145.0,Mid-Morning Market Update: Markets Open Higher; TJX Earnings Top Estimates,2019-05-21 10:12:00-04:00,OCUL,positive
946146.0,"Benzinga's Top Upgrades, Downgrades For May 21, 2019",2019-05-21 09:16:00-04:00,OCUL,positive
946147.0,Ocular Therapeutix shares are trading lower after the company reported its Phase 3 trail of OTX-TP for glaucome treatment did not meet its primary endpoint. Cowen and Raymond James downgraded the stock.,2019-05-21 08:58:00-04:00,OCUL,neutral
946148.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-05-21 08:06:00-04:00,OCUL,neutral
946149.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,OCUL,negative
946150.0,"Raymond James Downgrades Ocular Therapeutix, Inc. - Common Stock to Outperform",2019-05-21 07:22:00-04:00,OCUL,neutral
946151.0,"Cowen & Co. Downgrades Ocular Therapeutix, Inc. - Common Stock to Market Perform",2019-05-21 07:00:00-04:00,OCUL,neutral
946152.0,Ocular Therapeutix shares are trading lower after the company reported its Phase 3 trial of OTX-TP for treatment of glaucoma did not meet its primary endpoint.,2019-05-20 16:38:00-04:00,OCUL,neutral
946153.0,"Ocular Therapeutix Shares Resume Trade, Fall ~24%",2019-05-20 16:36:00-04:00,OCUL,positive
946154.0,Ocular Therapeutix Shares To Resume Trade At 4:35 p.m. EDT,2019-05-20 16:09:00-04:00,OCUL,positive
946155.0,Ocular Therapeutix Says Phase 3 Trial OF OTX-TP For Treatment Of Glaucoma Did Not Meet Primary Endpoint,2019-05-20 16:05:00-04:00,OCUL,neutral
946156.0,Ocular Therapeutix Shares Halted News Pending,2019-05-20 16:00:00-04:00,OCUL,positive
946157.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,OCUL,negative
946158.0,"Ocular Therapeutix Q1 EPS $(0.41) Beats $(0.42) Estimate, Sales $492K Beat $430K Estimate",2019-05-10 07:40:00-04:00,OCUL,neutral
946159.0,Ocular Therapeutix Announces DEXTENZA Recommended For Unique J-Code By CMS,2019-05-01 08:39:00-04:00,OCUL,positive
946160.0,"Ocular Therapeutix, Inc. Settles Litigation With Mati Therapeutics, Inc.",2019-04-30 09:23:00-04:00,OCUL,negative
946161.0,Ocular Therapeutix Highlights Presentation Of New Data At Association for Research in Vision and Ophthalmology Annual Meeting,2019-04-24 08:04:00-04:00,OCUL,positive
946162.0,"5 Stocks To Watch For April 8, 2019",2019-04-08 04:54:00-04:00,OCUL,neutral
946163.0,Ocular Therapeutix Filing Shows Registration For $50M Common Stock Offering,2019-04-05 16:56:00-04:00,OCUL,neutral
946164.0,"UPDATE: Ocular Therapeutix Reports PDUFA Date Set For Nov. 10, 2019",2019-04-02 08:17:00-04:00,OCUL,neutral
946165.0,Ocular Therapeutix Reports Notification Of FDA Acceptance Of Supplemental New Drug Submission For DEXTENZA For Treatment of Ocular Inflammation Following Ophthalmic Surgery,2019-04-02 08:16:00-04:00,OCUL,positive
946166.0,Ocular Therapeutix Filing Shows Registration For ~9.57M Share Common Stock Offering Via Selling Shareholders,2019-04-01 16:39:00-04:00,OCUL,positive
946167.0,"Ocular Therapeutix Q4 EPS $(0.42) Misses $(0.38) Estimate, Sales $504K Beat $480K Estimate",2019-03-07 16:11:00-05:00,OCUL,negative
946168.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,OCUL,negative
946169.0,"Ocular Therapeutix 13D Filing From Summer Road Shows Raised Stake From ~3.78M Shares To ~9.57M Shares, Or 17.8% Stake",2019-03-04 17:34:00-05:00,OCUL,positive
946170.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-03-03 09:41:00-05:00,OCUL,neutral
946171.0,72 Biggest Movers From Yesterday,2019-02-26 05:31:00-05:00,OCUL,neutral
946172.0,42 Stocks Moving In Monday's Mid-Day Session,2019-02-25 12:25:00-05:00,OCUL,neutral
946173.0,71 Biggest Movers From Friday,2019-02-25 05:04:00-05:00,OCUL,neutral
946174.0,"Ocular Therapeutix shares are trading higher after the company priced a $37.5 million convertible debt financing with an accredited investor, minimizing dilution and raising the company cash position by over 60%.",2019-02-22 10:02:00-05:00,OCUL,negative
946175.0,Ocular Therapeutix Reports Dosing Of First Patient In OTX-TKI Phase 1 Trial For Treatment Of Wet AMD,2019-02-20 08:30:00-05:00,OCUL,neutral
946176.0,Ocular Therapeutix Shares Tick Slightly Lower As Traders Circulating Unconfirmed Word Of FDA Warning Letter,2019-02-13 10:56:00-05:00,OCUL,negative
946177.0,"Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019",2019-01-24 10:05:00-05:00,OCUL,negative
946178.0,"The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA",2019-01-11 08:38:00-05:00,OCUL,negative
946179.0,Ocular Therapeutix Submits Supplemental New Drug Application For DEXTENZA For Treatment Of Ocular Inflammation Following Ophthalmic Surgery,2019-01-10 16:01:00-05:00,OCUL,neutral
946180.0,"Purdue Pharma L.P. And Ocular Therapeutix, Inc. Announce Initiation Of Collaborative Research Activities To Evaluate Innovative Formulations For Non-Opioid Treatments For Pain",2019-01-07 09:06:00-05:00,OCUL,negative
946181.0,33 Stocks Moving In Monday's Mid-Day Session,2018-12-31 12:19:00-05:00,OCUL,neutral
946182.0,"5 Stocks To Watch For December 31, 2018",2018-12-31 04:43:00-05:00,OCUL,neutral
946183.0,Ocular Therapeutix Filing Shows Registration For $200M Mixed Securities Offering,2018-12-28 16:16:00-05:00,OCUL,positive
946184.0,56 Biggest Movers From Yesterday,2018-12-04 05:02:00-05:00,OCUL,neutral
946185.0,46 Stocks Moving In Monday's Mid-Day Session,2018-12-03 12:37:00-05:00,OCUL,neutral
946186.0,Mid-Morning Market Update: Markets Open Higher; Nexstar to buy Tribune Media for $46.50/Share,2018-12-03 10:13:00-05:00,OCUL,neutral
946187.0,"Cantor Fitzgerald Reiterates Overweight Rating On Ocular Therapeutics Following FDA Approval Of DEXTENZA; Firm Says Following Approval, Co. Can Now Shift Focus To Commercialization Efforts",2018-12-03 09:45:00-05:00,OCUL,positive
946188.0,Ocular Therapeutix Shares Resume Trading,2018-12-03 07:31:00-05:00,OCUL,positive
946189.0,Ocular Therapeutix Announces FDA Approval of DEXTENZA,2018-12-03 07:12:00-05:00,OCUL,positive
946190.0,52 Biggest Movers From Friday,2018-12-03 05:42:00-05:00,OCUL,neutral
946191.0,Ocular Therapeutix Shares Halted News Pending,2018-11-30 16:06:00-05:00,OCUL,positive
946192.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2018-11-30 13:09:00-05:00,OCUL,neutral
946193.0,38 Stocks Moving In Friday's Mid-Day Session,2018-11-30 12:33:00-05:00,OCUL,neutral
946194.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,OCUL,negative
946195.0,"Ocular Therapeutix Q3 EPS $(0.38), Inline, Sales $498K Beat $470K Estimate",2018-11-07 16:15:00-05:00,OCUL,neutral
946196.0,"Ocular Therapeutix Receives FDA Warning Letter Related To ReSure Sealant; Letter Relates To Co.'s Compliance With Data Collection And Information Reporting, Co. Says Working To Address And Resolve Concerns",2018-10-19 07:52:00-04:00,OCUL,positive
946197.0,"Ocular Therapeutix Q2 GAAP EPS $(0.37) May Not Compare To $(0.38) Estimate, Sales $648K Beat $380K Estimate",2018-08-07 17:28:00-04:00,OCUL,neutral
946198.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,OCUL,negative
946199.0,"Ocular Therapeutix Reports FDA Acceptance Of New Drug Application Resubmission For DEXTENZA; PDUFA Date Set For Dec. 28, 2018",2018-07-19 08:04:00-04:00,OCUL,positive
946200.0,38 Stocks Moving In Monday's Mid-Day Session,2018-07-02 12:29:00-04:00,OCUL,neutral
946201.0,'$OCUL needed one full year to correct manufacturing issues and resubmit. Good reminder that CMC stuff matters.' -Tweet From STAT News' Adam Feuerstein,2018-06-29 08:16:00-04:00,OCUL,positive
946202.0,'$OCUL needed one full year to correct manufacturing issues and resubmit. Good reminder that CMC stuff matters.'-STAT's Adam Feuerstein Tweets,2018-06-29 08:12:00-04:00,OCUL,positive
946203.0,Ocular Therapeutix Reports New Drug Application Resubmission Of DEXTENZA,2018-06-29 08:01:00-04:00,OCUL,neutral
946204.0,Ocular Therapeutix Shares Down 10.7% After Hours Following Q1 Miss,2018-05-08 17:42:00-04:00,OCUL,positive
946205.0,"Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.38) Estimate, Sales $340K Miss $450K Estimate",2018-05-08 16:04:00-04:00,OCUL,negative
946206.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,OCUL,neutral
946207.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,OCUL,neutral
946208.0,Ocular Therapeutix Treats 1st Patient in Phase 1 Clinical Trial of OTX-TIC,2018-05-03 08:39:00-04:00,OCUL,neutral
946209.0,"Ocular Therapeutix Reports Q4 EPS $(0.44) vs $(0.52) Est., $487K vs $520K Est.",2018-03-08 07:30:00-05:00,OCUL,neutral
946210.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,OCUL,neutral
946211.0,44 Biggest Movers From Yesterday,2018-01-26 04:43:00-05:00,OCUL,neutral
946212.0,34 Stocks Moving In Thursday's Mid-Day Session,2018-01-25 13:29:00-05:00,OCUL,neutral
946213.0,Benzinga Pro's 4 Stocks To Watch Today,2018-01-25 09:11:00-05:00,OCUL,neutral
946214.0,Ocular TherapeutixTM Prices 6.5M Share Offering At $5/Share,2018-01-25 09:09:00-05:00,OCUL,positive
946215.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-01-25 08:06:00-05:00,OCUL,neutral
946216.0,"A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Earnings, Economic Data",2018-01-25 07:09:00-05:00,OCUL,positive
946217.0,"12 Stocks To Watch For January 25, 2018",2018-01-25 05:22:00-05:00,OCUL,neutral
946218.0,11 Stocks Moving In Wednesday's After-Hours Session,2018-01-24 17:29:00-05:00,OCUL,neutral
946219.0,"Ocular Therapeutix Announces Common Stock Offering, No Size Disclosed",2018-01-24 16:25:00-05:00,OCUL,negative
946220.0,34 Biggest Movers From Friday,2018-01-22 04:30:00-05:00,OCUL,neutral
946221.0,28 Stocks Moving In Friday's Mid-Day Session,2018-01-19 13:00:00-05:00,OCUL,neutral
946222.0,"Benzinga's Top Upgrades, Downgrades For January 19, 2018",2018-01-19 10:03:00-05:00,OCUL,positive
946223.0,14 Stocks Moving In Friday's Pre-Market Session,2018-01-19 09:22:00-05:00,OCUL,neutral
946224.0,BTIG Research Upgrades Ocular Therapeutix to Buy,2018-01-19 07:18:00-05:00,OCUL,neutral
946225.0,38 Biggest Movers From Friday,2018-01-16 05:26:00-05:00,OCUL,neutral
946226.0,"Ocular Therapeutix Gives Update On Current Legal Proceedings, Says Co. Received A Subpoena Requesting Documents And Info Concerning DEXTENZA Including Communications With The FDA, Investors, And Others",2017-12-22 16:06:00-05:00,OCUL,positive
946227.0,"Ocular Therapeutix Reports Q3 EPS $(0.54) vs $(0.53) Est., Sales $523K vs $510K Est.",2017-11-07 17:04:00-05:00,OCUL,neutral
946228.0,"Guggenheim Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces $12.00 Price Target",2017-10-24 09:17:00-04:00,OCUL,neutral
946229.0,Ocular Therapeutix Names Donald Notman CFO,2017-09-25 08:04:00-04:00,OCUL,neutral
946230.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,OCUL,neutral
946231.0,Ocular Therapeutix Names Dr. Michael Goldstein As Chief Medical Officer,2017-09-08 09:01:00-04:00,OCUL,neutral
946232.0,"Ocular Therapeutix Reports Q2 GAAP EPS $(0.64) May Not Compare To $(0.56) Est., Sales $438K",2017-08-08 16:23:00-04:00,OCUL,neutral
946233.0,Ocular Therapeutix Names Antony Mattessich CEO,2017-08-01 16:25:00-04:00,OCUL,neutral
946234.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,OCUL,neutral
946235.0,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",2017-07-26 09:25:00-04:00,OCUL,positive
946236.0,"H.C. Wainwright Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces $10.00 Price Target",2017-07-26 07:13:00-04:00,OCUL,neutral
946237.0,Adam Feuerstein Tweets: $OCUL straphangers should read this Seeking Alpha story on hidden risk in glaucoma ph3 study —> seekingalpha.com/article/408774… Changed ph3 endpoint,2017-07-14 12:31:00-04:00,OCUL,negative
946238.0,Mid-Afternoon Market Update: NASDAQ Up Over 1%; MSC Industrial Shares Plummet,2017-07-12 14:33:00-04:00,OCUL,positive
946239.0,10 Biggest Mid-Day Losers For Wednesday,2017-07-12 12:50:00-04:00,OCUL,negative
946240.0,Mid-Day Market Update: Ocular Therapeutix Drops After Major Setback In Dextenza; I.D. Systems Shares Surge,2017-07-12 12:34:00-04:00,OCUL,positive
946241.0,"Adam Feuerstein Tweets: Amazed $OCUL down just 20% to $6. If they can't manufacture Dextenza, hopes for future glaucoma product should lie shattered on floor.",2017-07-12 11:34:00-04:00,OCUL,negative
946242.0,Cantor Remains Confident On Ocular Therapeutix Despite Big Decline,2017-07-12 10:01:00-04:00,OCUL,positive
946243.0,Ocular Therapeutix Falls 30% After Major Setback In Dextenza,2017-07-12 08:38:00-04:00,OCUL,neutral
946244.0,Ocular Therapeutix Shares Down 32.8% In Pre-Market Following Tuesday Report Of CRL Received From FDA For DEXTENZA NDA,2017-07-12 08:22:00-04:00,OCUL,positive
946245.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-07-12 08:06:00-04:00,OCUL,neutral
946246.0,Ocular Therapeutix Shares To Resume Trade At 5:30 p.m. EDT,2017-07-11 17:08:00-04:00,OCUL,positive
946247.0,Ocular Therapeutix Reports Received CRL From FDA For DEXTENZA NDA,2017-07-11 17:00:00-04:00,OCUL,neutral
946248.0,Ocular Therapeutics Shares Halted News Pending,2017-07-11 16:59:00-04:00,OCUL,positive
946249.0,12 Biggest Mid-Day Gainers For Tuesday,2017-07-11 12:24:00-04:00,OCUL,neutral
946250.0,Ocular Therapeutix Shares Up 20.8% Following Monday Submission Of Amendment To Potentially Extend Review For DEXTENZA NDA,2017-07-11 09:43:00-04:00,OCUL,positive
946251.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-07-11 08:10:00-04:00,OCUL,neutral
946252.0,Ocular Therapeutix Reports Submission Of Amendment To Potentially Extend Review For DEXTENZA NDA,2017-07-10 16:16:00-04:00,OCUL,positive
946253.0,12 Biggest Mid-Day Losers For Monday,2017-07-10 13:01:00-04:00,OCUL,negative
946254.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-10 08:24:00-04:00,OCUL,neutral
946255.0,Adam Feuerstein Reports 'Ocular Therapeutix still working on manufacturing fix for eye drug with FDA deadline approaching',2017-07-07 15:35:00-04:00,OCUL,neutral
946256.0,15 Biggest Mid-Day Losers For Friday,2017-07-07 12:59:00-04:00,OCUL,negative
946257.0,20 Stocks Moving In Friday's Pre-Market Session,2017-07-07 08:12:00-04:00,OCUL,neutral
946258.0,Adam Feuerstein Tweets: $OCUL FDA approval imperiled by drug contamination concerns —> statnews.com/2017/07/06/ocu… Aluminum contaminating Dextenza batches.,2017-07-06 12:57:00-04:00,OCUL,positive
946259.0,Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days,2017-07-05 11:01:00-04:00,OCUL,neutral
946260.0,12 Biggest Mid-Day Losers For Friday,2017-06-23 13:06:00-04:00,OCUL,negative
946261.0,Mid-Morning Market Update: Markets Mostly Flat; BlackBerry Sales Miss Views,2017-06-23 10:15:00-04:00,OCUL,negative
946262.0,"Benzinga's Top Upgrades, Downgrades For June 23, 2017",2017-06-23 09:23:00-04:00,OCUL,positive
946263.0,The Market In 5 Minutes,2017-06-23 09:00:00-04:00,OCUL,neutral
946264.0,20 Stocks Moving In Friday's Pre-Market Session,2017-06-23 08:19:00-04:00,OCUL,neutral
946265.0,Morgan Stanley Downgrades Ocular Therapeutix to Equal-Weight,2017-06-23 06:35:00-04:00,OCUL,neutral
946266.0,"Ocular Therapeutix Announces Amar Sawhney To Transition To Sole Role Of Chair, Antony Mattessich To Succeed Sawhney As CEO",2017-06-22 16:11:00-04:00,OCUL,positive
946267.0,Dear Avi: Should I Buy An IPO?,2017-06-15 11:11:00-04:00,OCUL,positive
946268.0,"Jefferies Health Care Conference Concludes Today, Presenters Include: Mazor Robotic, bluebird bio, and Ocular Therapeutix",2017-06-09 07:51:00-04:00,OCUL,positive
946269.0,Ocular Therapeutix Reports FDA Has Set July 19 PDUFA Date For DEXTENZA NDA,2017-05-11 08:10:00-04:00,OCUL,neutral
946270.0,"Ocular Therapeutix Offers Preclinical Data on Pharmokinetics, EFficacy, Tolerability of OTX-TKI at ARVO Annual Meeting",2017-05-09 14:50:00-04:00,OCUL,neutral
946271.0,"Ocular Therapeutix's Manufacturing Inspection: Items Of Concern Are 'Addressable,' Shouldn't Delay Product Launch",2017-05-08 08:59:00-04:00,OCUL,positive
946272.0,"UPDATE: Ocular Therapeutix Says FDA Set PDUFA Data of Jul. 19, 2017",2017-05-08 08:13:00-04:00,OCUL,neutral
946273.0,"Ocular Therapeutix Reports Presentation of Added Data from Most Recent Phase 3 Study Evaluating Safety, Efficacy of DEXTENZA 0.4 mg for Treatment of Ocular Pain, Inflammation Following Cataract Surgery",2017-05-08 08:12:00-04:00,OCUL,negative
946274.0,BTIG Research Downgrades Ocular Therapeutix to Neutral,2017-05-05 14:41:00-04:00,OCUL,neutral
946275.0,"Ocular Therapeutix Reports Q1 EPS $(0.58) vs $(0.48) Est., Sales $475K vs $470K Est.",2017-05-05 07:38:00-04:00,OCUL,neutral
946276.0,Ocular Therapeutix Names George Migausky Interim CFO,2017-04-06 08:03:00-04:00,OCUL,neutral
946277.0,Ocular Therapeutix CFO Bradford Smith To Resign,2017-03-20 16:41:00-04:00,OCUL,negative
946278.0,20 Biggest Mid-Day Losers For Friday,2017-03-17 13:02:00-04:00,OCUL,negative
946279.0,20 Stocks Moving In Friday's Pre-Market Session,2017-03-17 08:24:00-04:00,OCUL,neutral
946280.0,"Ocular Therapeutix Issues Press Release Discussing Intent for Study with DEXTENZA, Offers 4 Bullets Describing Patient's Experience During Study",2017-03-15 08:14:00-04:00,OCUL,neutral
946281.0,"Ocular Therapeutix Reports Q4 EPS $(0.52) vs $(0.45) Est., Sales $511K vs $490K Est.",2017-03-10 07:31:00-05:00,OCUL,neutral
946282.0,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",2017-03-07 08:59:00-05:00,OCUL,neutral
946283.0,"RBC Capital Markets Healthcare Conference Concludes Today; Presenters Include Spark Therapeutics, Johnson & Johnson, HCA Holdings, Ocular Therapeutix, Valeant & Agile Therapeutics",2017-02-23 08:04:00-05:00,OCUL,positive
946284.0,Ocular Therapeutix Reports FDA Acceptance of NDA Resubmission for DEXTENZA,2017-02-22 08:03:00-05:00,OCUL,positive
946285.0,Ocular Sciences Falls to Low of $9.66 on Volue,2017-02-21 10:14:00-05:00,OCUL,negative
946286.0,"Bio CEO & Investor Conference Begins Today; Presenters Include Inovio Pharmaceuticals, Agile Therapeutics, CytRx, Eiger Biopharmaceuticals, Neurotrope, & Ocular Therapeutix",2017-02-13 08:36:00-05:00,OCUL,neutral
946287.0,20 Biggest Mid-Day Gainers For Friday,2017-02-10 13:25:00-05:00,OCUL,neutral
946288.0,"Benzinga's Top Upgrades, Downgrades For February 10, 2017",2017-02-10 09:32:00-05:00,OCUL,positive
946289.0,"Cantor Fitzgerald Initiates Coverage On Ocular Therapeutix At Overweight, Announces $35 Price Target",2017-02-10 08:41:00-05:00,OCUL,negative
946290.0,30 Stocks Moving In Friday's Pre-Market Session,2017-02-10 08:39:00-05:00,OCUL,neutral
946291.0,15 Biggest Mid-Day Losers For Tuesday,2017-01-24 12:59:00-05:00,OCUL,negative
946292.0,Ocular Therapeutix Lower After 3.5 Million Share Offering,2017-01-24 12:19:00-05:00,OCUL,neutral
946293.0,Mid-Day Market Update: Genvec Jumps Following Announcement of Acquisition By Intrexon; BT Group Shares Drop,2017-01-24 12:05:00-05:00,OCUL,neutral
946294.0,Mid-Morning Market Update: Markets Open Higher; Verizon Earnings Miss Expectations,2017-01-24 09:50:00-05:00,OCUL,negative
946295.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-01-24 08:24:00-05:00,OCUL,neutral
946296.0,Ocular Therapeutic Prices 3.5M Shares At $7/Share,2017-01-24 08:00:00-05:00,OCUL,positive
946297.0,Ocular Therapeutix Reports Offering of $25M in Common Shares,2017-01-23 16:01:00-05:00,OCUL,positive
946298.0,8-K from Ocular Therapeutix Shows Co. Resubmitted NDA to FDA For DEXTENZA 0.4 mg for Treatment of Ocular Pain Occurring After Ophthalmic Surgery,2017-01-23 08:28:00-05:00,OCUL,negative
946299.0,Ocular Therapeutix Resubmits NDA for DEXTENZA For Ocular Pain Treatment Following Ophthalmic Surgery,2017-01-23 08:17:00-05:00,OCUL,negative
946300.0,Technical Alert: Ocular Therapeutix Higher Off Positive Data,2017-01-04 09:54:00-05:00,OCUL,positive
946301.0,Ocular Therapeutix Reports Statistically Significant Secondary Endpoint Of Absence Of Ocular Flare Confirms Further Evidence Of Reduction Of Inflammation,2017-01-04 08:03:00-05:00,OCUL,positive
946302.0,15 Biggest Mid-Day Gainers For Monday,2016-12-19 12:43:00-05:00,OCUL,neutral
946303.0,25 Stocks Moving In Wednesday's Pre-Market Session,2016-11-30 08:28:00-05:00,OCUL,neutral
946304.0,20 Stocks Moving In Tuesday's Pre-Market Session,2016-11-29 08:22:00-05:00,OCUL,neutral
946305.0,12 Biggest Mid-Day Losers For Monday,2016-11-28 13:05:00-05:00,OCUL,negative
946306.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-28 08:24:00-05:00,OCUL,neutral
946307.0,Technical Alert: Ocular Therapeutix Finds Support And Resistance,2016-11-21 11:56:00-05:00,OCUL,positive
946308.0,15 Stocks Moving In Monday's Pre-Market Session,2016-11-21 08:33:00-05:00,OCUL,neutral
946309.0,Ocular Therapeutics Spikes to High of $10.14 on Volume,2016-11-18 11:12:00-05:00,OCUL,neutral
946310.0,Ocular Therapeutix Higher For Seventh Day In A Row,2016-11-16 12:33:00-05:00,OCUL,neutral
946311.0,18 Biggest Mid-Day Gainers For Monday,2016-11-14 12:30:00-05:00,OCUL,neutral
946312.0,Ocular Therapeutix Higher Off Positive Results For Dextenza,2016-11-14 10:33:00-05:00,OCUL,positive
946313.0,18 Stocks Moving In Monday's Pre-Market Session,2016-11-14 08:23:00-05:00,OCUL,neutral
946314.0,"Ocular Therapeutix Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA, Met Both Primary Endpoints",2016-11-14 07:06:00-05:00,OCUL,positive
946315.0,"Ocular Therapeutix Reports Q3 EPS $(0.39) vs. Est. $(0.50), Rev. $477K vs. Est. $470K",2016-11-09 07:08:00-05:00,OCUL,neutral
946316.0,Deal With Regeneron Means Validation For Ocular Therapeutix,2016-10-13 15:07:00-04:00,OCUL,neutral
946317.0,Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop,2016-10-13 14:48:00-04:00,OCUL,positive
946318.0,Technical Alert: Ocular Therapeutix Pares Early Gains,2016-10-13 13:34:00-04:00,OCUL,positive
946319.0,10 Biggest Mid-Day Gainers For Thursday,2016-10-13 12:29:00-04:00,OCUL,neutral
946320.0,Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide,2016-10-13 12:02:00-04:00,OCUL,positive
946321.0,Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates,2016-10-13 10:03:00-04:00,OCUL,positive
946322.0,Ocular Therapeutix Shares Charge Higher Following Collaboration Deal With Regeneron,2016-10-13 09:31:00-04:00,OCUL,positive
946323.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-13 08:48:00-04:00,OCUL,neutral
946324.0,Ocular Therapeutix Shares to Resume Trade at 7:30 a.m. EDT,2016-10-13 07:26:00-04:00,OCUL,positive
946325.0,UPDATE: Ocular Therapeutix Will Receive  up to $305M in Milestone Payments in Addition to Royalties on Potential Future Net Sales,2016-10-13 07:05:00-04:00,OCUL,neutral
946326.0,"Ocular Therapeutix, Regeneron Report Entering Into of Strategic Collaboration for Developing Sustained Release Formulation of Aflibercept for Treatment of Wet AMD, Other Serious Retinal Diseases",2016-10-13 07:04:00-04:00,OCUL,negative
946327.0,Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP  for the Treatment of Glaucoma and Ocular Hypertension,2016-10-04 16:05:00-04:00,OCUL,neutral
946328.0,20 Biggest Mid-Day Losers For Tuesday,2016-08-16 13:23:00-04:00,OCUL,negative
946329.0,20 Stocks Moving In Tuesday's Pre-Market Session,2016-08-16 08:30:00-04:00,OCUL,neutral
946330.0,15 Biggest Mid-Day Gainers For Monday,2016-08-15 12:39:00-04:00,OCUL,neutral
946331.0,12 Stocks Moving In Monday's Pre-Market Session,2016-08-15 08:25:00-04:00,OCUL,neutral
946332.0,Ocular Therapeutix +12% Premarket @ $7.60,2016-08-15 08:19:00-04:00,OCUL,neutral
946333.0,18 Biggest Mid-Day Gainers For Friday,2016-08-12 12:39:00-04:00,OCUL,neutral
946334.0,18 Stocks Moving In Friday's Pre-Market Session,2016-08-12 08:19:00-04:00,OCUL,neutral
946335.0,18 Biggest Mid-Day Gainers For Thursday,2016-08-11 12:50:00-04:00,OCUL,neutral
946336.0,Benzinga's Top Initiations,2016-08-11 09:22:00-04:00,OCUL,positive
946337.0,22 Stocks Moving In Thursday's Pre-Market Session,2016-08-11 08:24:00-04:00,OCUL,neutral
946338.0,JMP Securities Initiates Coverage on Ocular Therapeutix at Outperform,2016-08-11 07:32:00-04:00,OCUL,positive
946339.0,"Ocular Therapeutix Reports Q2 EPS $(0.46) vs $(0.49) Est., Sales $441K vs $550K Est.",2016-08-09 07:37:00-04:00,OCUL,neutral
946340.0,A Handful of Biotech Stocks Plunge After Disappointing Results,2016-08-08 16:51:00-04:00,OCUL,negative
946341.0,11 Stocks Moving In Monday's Pre-Market Session,2016-08-08 08:26:00-04:00,OCUL,neutral
946342.0,20 Biggest Mid-Day Gainers For Thursday,2016-08-04 12:49:00-04:00,OCUL,neutral
946343.0,Mid-Morning Market Update: Markets Edge Lower; Viacom Tops Q3 Expectations,2016-08-04 10:05:00-04:00,OCUL,positive
946344.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-04 08:35:00-04:00,OCUL,neutral
946345.0,Ocular Therapeutix +26% Premarket @ $5.29; FDA Said Corrective Actions Received in Response to CRL Appear to Mostly Address the Ten  inspectional Observations Raised in Form FDA 483,2016-08-04 08:21:00-04:00,OCUL,neutral
946346.0,"After-Hours Gainers Aug. 3, '16: OCUL Up 22%, SQ 14.9%, CBMX 13.5%, AXGN 10%, AVID 8.7%, PODD 8.6%, NSTG 8.3%, JACK 8%, EXEL 7.7%",2016-08-03 19:10:00-04:00,OCUL,positive
946347.0,Ocular Therapeutix Receives CRL On NDA For DEXTENZA Due To One Outstanding Item Pertaining To Manufacturing Process And Controls,2016-08-03 17:25:00-04:00,OCUL,positive
946348.0,Ocular Therapeutix Provides Update on NDA for Dextenza; FDA Says Corrective Actions Receive in Response to CRL Appear to Address the Ten  inspectional Observations Raised in Form FDA 483 With One Exception,2016-08-03 16:45:00-04:00,OCUL,neutral
946349.0,10 Biggest Mid-Day Losers For Monday,2016-07-25 13:01:00-04:00,OCUL,negative
946350.0,Ocular Therapeutix Gets Complete Response Letter From FDA For Its NDA For DEXTENZA,2016-07-25 09:57:00-04:00,OCUL,neutral
946351.0,13 Stocks Moving In Monday's Pre-Market Session,2016-07-25 08:25:00-04:00,OCUL,neutral
946352.0,"Ocular Therapeutix Receives CRL from FDA for its NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain, No Efficacy Or Safety Issues Raised By FDA; Outstanding Items Due To Manufacturing Process & Controls",2016-07-25 08:02:00-04:00,OCUL,positive
946353.0,Jennison Associates Reports 12% Passive Stake in Ocular Therapeutix in 13G,2016-07-08 11:00:00-04:00,OCUL,positive
946354.0,Cowen Says Ocular Therapeutix's OTX-DP Miss 'Meaningless' To Bull Thesis,2016-06-06 14:36:00-04:00,OCUL,negative
946355.0,Monday's 7 Biggest Mid-Day Losers,2016-06-06 12:44:00-04:00,OCUL,negative
946356.0,Mid-Day Market Update: Dow Surges Over 100 Points; Adamis Pharmaceuticals Shares Slide,2016-06-06 12:05:00-04:00,OCUL,positive
946357.0,"UPDATE: Cowen on Ocular Therapeutix: 'Although any clinical trial failure of any kind is always a disappointment, in this instance, the OTX-DP miss in allergic conjunctivitis is meaningless to our thesis.'",2016-06-06 12:05:00-04:00,OCUL,negative
946358.0,"Oculus Therapeutix Shares Edge Slightly Higher Over Last Few Mins as Hearing Cowen Has Issued Mid-Day Note Reiterating Buy, $60 Target",2016-06-06 11:59:00-04:00,OCUL,positive
946359.0,These 3 Biotech Stocks Are Getting Killed Today,2016-06-06 10:58:00-04:00,OCUL,negative
946360.0,Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around $1 Billion,2016-06-06 10:09:00-04:00,OCUL,positive
946361.0,10 Stocks Moving In Monday's Pre-Market Session,2016-06-06 08:30:00-04:00,OCUL,neutral
946362.0,"Ocular Therapeutics, ProNai Therapeutics To Resume Trade At 7:30am ET",2016-06-06 07:26:00-04:00,OCUL,neutral
946363.0,"UPDATE: Ocular Therapeutix Reports Phase 3 Clinical Trial Of DEXTENZA For Allergic Conjunctivitis; Did Not Meet Primary Endpoint, Conf. Call At 8:30am ET Today",2016-06-06 07:02:00-04:00,OCUL,negative
946364.0,Ocular Therapeutics Phase 3 DEXTENZA Clinical Trial Did Not Meet Primary Endpoint,2016-06-06 07:01:00-04:00,OCUL,neutral
946365.0,Ocular Therapeutix Reports Q1 EPS $(0.44) vs. Est. $(0.43),2016-05-10 07:17:00-04:00,OCUL,neutral
946366.0,"Ocular Therapeutix Reports Closing of End of Phase 2 Review with FDA for OTX-TP for Glaucoma, Ocular Hypertension",2016-04-27 17:05:00-04:00,OCUL,neutral
946367.0,Ocular TherapeutixTM Reports Q4 EPS $(0.43) vs. Est. $(0.47),2016-03-10 07:08:00-05:00,OCUL,neutral
946368.0,"Morgan Stanley Upgrades Ocular Therapeutix to Overweight, Maintains $15.00 PT",2016-02-18 04:05:00-05:00,OCUL,negative
946369.0,Ocular Therapeutix Spikes 45% On Drug News; Morgan Stanley Upgraded Co. To Overweight,2016-02-17 13:47:00-05:00,OCUL,negative
946370.0,Morgan Stanley Upgrades Ocular Therapeutix Following Guidance For A Pathway Forward With OTX-TP,2016-02-17 08:20:00-05:00,OCUL,neutral
946371.0,"Morgan Stanley Upgrades Ocular Therapeutix to Overweight, Maintains $15.00 PT",2016-02-17 08:17:00-05:00,OCUL,negative
946372.0,"Oculus Therapeutix Announces Phase 3 Clinical Development Plan, First 2 Planned Phase 3 Clinical Trials To Commence In Q3 2016",2016-02-16 16:38:00-05:00,OCUL,neutral
946373.0,Ocular Therapeutix Trading Lower,2015-12-29 14:28:00-05:00,OCUL,negative
946374.0,"Ocular Therapeutics Reports Encouraging Top-Line Results from Exploratory Phase 2 Trial of DEXTENZA: Showed Benefit in Efficacy Measure, Meaningful Benefit from Supportive Measures",2015-12-14 07:03:00-05:00,OCUL,positive
946375.0,16 Stocks Moving In Friday's After-Hours Session,2015-12-11 17:03:00-05:00,OCUL,neutral
946376.0,Ocular Therapeutix Reports FDA Acceptance of NDA Filing for DEXTENZA for the Treatment of Post-Surgical Ocular Pain,2015-12-09 08:02:00-05:00,OCUL,negative
946377.0,10 Stocks To Watch In Friday's After-Hours Session,2015-12-04 16:58:00-05:00,OCUL,neutral
946378.0,Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis,2015-11-24 08:00:00-05:00,OCUL,negative
946379.0,Morning Market Losers,2015-11-11 10:06:00-05:00,OCUL,negative
946380.0,"Ocular Therapeutix Reports Q3 EPS $(0.47) vs. Est. $(0.38), Rev. $429K vs. Est. $500K",2015-11-10 16:18:00-05:00,OCUL,neutral
946381.0,"Ocular Therapeutics Shares Sell Off Below $9, Currently $9.05",2015-11-02 12:01:00-05:00,OCUL,positive
946382.0,"Ocular Therapeutix Reports Results from Phase 2b Glaucoma Trial Showed Clinically Meaningful Intraocular Pressure Reduction, Improvement in Depot Retention Showed with OTX-TP at Day 75",2015-10-22 16:36:00-04:00,OCUL,positive
946383.0,"Ocular Therapeutix Reports Results of Phase 3 Trial for DEXTENZA in Allergic Conjunctivitis, Says Met Primary Endpoint",2015-10-22 16:34:00-04:00,OCUL,negative
946384.0,Ocular Therapeutix Starts Enrollment in Third Phase 3 Clinical Trial for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain,2015-10-14 16:05:00-04:00,OCUL,negative
946385.0,Ocular Therapeutix Offers Submission of NDA to FDA for DEXTENZA for Treatment of Post-Surgical Ocular Pain,2015-09-28 08:01:00-04:00,OCUL,negative
946386.0,"Ocular Therapeutix Adds Jeffrey S. Heier, M.D. To Board",2015-09-14 16:06:00-04:00,OCUL,neutral
946387.0,"Morgan Stanley Initiates Coverage on Ocular Therapeutix at Equal-weight, Announces $24.00 PT",2015-08-13 04:35:00-04:00,OCUL,neutral
946388.0,"Ocular Therapeutix Reports Q2 Loss of $0.45/Share vs Loss of $0.33/Share Est., Sales $459K vs $400K Est.",2015-08-10 16:09:00-04:00,OCUL,negative
946389.0,Benzinga's Top Initiations,2015-08-05 10:32:00-04:00,OCUL,positive
946390.0,"Nomura Initiates Coverage on Ocular Therapeutix at Buy, Announces $46.00 PT",2015-08-05 07:59:00-04:00,OCUL,neutral
946391.0,13G Filing from Capital Research Global Partners on Ocular Therapeutix Shows New 11.5% Stake,2015-07-10 11:27:00-04:00,OCUL,neutral
946392.0,Ocular Therapeutix Reports Commencement of Enrollment for Phase 3 Trial of DEXTENZA for Treatment of Allergic Conjunctivitis,2015-06-16 07:31:00-04:00,OCUL,negative
946393.0,US Stock Futures Slip; All Eyes On Jobs Report,2015-06-05 07:22:00-04:00,OCUL,neutral
946394.0,Ocular Therapeutix Prices 4M Share Offering @$22.00/Share,2015-06-05 04:30:00-04:00,OCUL,positive
946395.0,"Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock",2015-06-02 16:05:00-04:00,OCUL,neutral
946396.0,S-1 Filing From Ocular Therapeutix To Offer $120M Stock,2015-05-20 17:35:00-04:00,OCUL,neutral
946397.0,US Stock Futures Edge Higher Ahead Of Economic Data,2015-05-15 07:15:00-04:00,OCUL,neutral
946398.0,Ocular Therapeutixs Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication,2015-05-15 06:51:00-04:00,OCUL,negative
946399.0,Ocular Therapeutics Q1 EPS -$0.35 vs -$0.39 est,2015-05-15 06:46:00-04:00,OCUL,neutral
946400.0,"Earning, Economic & IPO Calendar for Friday May 15, 2015",2015-05-15 05:01:00-04:00,OCUL,neutral
946401.0,"Earnings Scheduled For May 15, 2015",2015-05-15 04:04:00-04:00,OCUL,neutral
946402.0,Biotech: Anatomy Of An Investing Mania?,2015-04-07 11:39:00-04:00,OCUL,neutral
946403.0,Morning Market Losers,2015-04-07 09:46:00-04:00,OCUL,negative
946404.0,"Ocular Therapeutix Shares Plunge Upon Resumption, Now Down ~22%",2015-04-06 17:01:00-04:00,OCUL,positive
946405.0,"Ocular To Resume Quoting Any Moment, Trading To Resume At 17:00 EDT",2015-04-06 16:54:00-04:00,OCUL,neutral
946406.0,UPDATE: Ocular Therapeutix Offers Topline Clinical Data for Second Phase 3 Trial of OTX-DP,2015-04-06 16:31:00-04:00,OCUL,neutral
946407.0,"Ocular Therapeutix Offers Topline Clinical Data for Second Phase 3 Trial of OTX-DP: Primary Efficacy Endpoint for Pain Met, for Inflammatory Cells Not Attained",2015-04-06 16:30:00-04:00,OCUL,negative
946408.0,Ocular Therapeutix Shares Halted News Pending,2015-04-06 16:29:00-04:00,OCUL,positive
946409.0,Adam F Cautious on Ocular Therapeutix,2015-03-10 10:21:00-04:00,OCUL,negative
946410.0,US Stock Futures Tumble Ahead Of Wholesale Inventories Data,2015-03-10 07:08:00-04:00,OCUL,neutral
946411.0,Ocular Therapeutix Q4 EPS -$0.37 vs -$0.38 est,2015-03-10 06:46:00-04:00,OCUL,neutral
946412.0,Ocular Therapeutix Reports Positive Topline Clinical Data for First of Two Phase 3 Clinical Trials Evaluating OTX-DP for Treatment of Post-Surgical Ocular Inflammation and Pain,2015-03-10 06:32:00-04:00,OCUL,positive
946413.0,"Earnings Scheduled For March 10, 2015",2015-03-10 05:38:00-04:00,OCUL,neutral
946414.0,IPO Outlook: Inotek's Vision For The Future,2015-02-04 14:28:00-05:00,OCUL,positive
946415.0,Stocks Hitting 52-Week Highs,2015-02-02 10:17:00-05:00,OCUL,neutral
946416.0,Ocular Therapeutix Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone,2015-01-21 08:03:00-05:00,OCUL,neutral
946417.0,Stocks Hitting 52-Week Highs,2014-12-16 10:24:00-05:00,OCUL,neutral
946418.0,US Stock Futures Slide Ahead Of Macy's Earnings,2014-11-12 07:03:00-05:00,OCUL,neutral
946419.0,Ocular Therapeutix Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension,2014-11-12 06:48:00-05:00,OCUL,neutral
946420.0,Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis,2014-11-12 06:32:00-05:00,OCUL,negative
946421.0,"Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014 ",2014-11-05 08:02:00-05:00,OCUL,neutral
946422.0,Ocular Therapeutix Completes Enrollment In Phase 3 Sustained Release Dexamethasone Trials For Post-Operative Inflammation And Pain,2014-10-08 08:02:00-04:00,OCUL,negative
946423.0,Benzinga's Top Initiations,2014-08-19 09:08:00-04:00,OCUL,positive
946424.0,Oppenheimer Initiates Ocular Therapeutix With Outperform,2014-08-19 08:08:00-04:00,OCUL,neutral
946425.0,"RBC Capital Initiates Coverage on Ocular Therapeutix at Outperform, Announces $21.00 PT",2014-08-19 06:33:00-04:00,OCUL,neutral
946426.0,"Oppenheimer Initiates Coverage on Ocular Therapeutix at Outperform, Announces $25.00 PT",2014-08-19 06:33:00-04:00,OCUL,neutral
946427.0,"Ocular Therapeutix Shares Open at $13, Priced IPO at $13/Share",2014-07-25 11:21:00-04:00,OCUL,positive
946428.0,Waiting on 5 IPOs This Morning,2014-07-25 08:09:00-04:00,OCUL,neutral
946429.0,"IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?",2014-07-21 16:37:00-04:00,OCUL,positive
946430.0,Ocular Therapeutics Expects 5M Share IPO to Price $14-$16/Share,2014-07-11 06:06:00-04:00,OCUL,positive
946431.0,Ocular Therapeutix Files up to $86.25M IPO,2014-06-20 14:49:00-04:00,OCUL,neutral
